相似文献
1
The M184V substitution in human immunodeficiency virus type 1 reverse transcriptase delays the development of resistance to amprenavir and efavirenz in subtype B and C clinical isolates.
Antimicrob Agents Chemother. 2003 Jul;47(7):2376-9. doi: 10.1128/AAC.47.7.2376-2379.2003.
2
Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT.
Antimicrob Agents Chemother. 2002 Jul;46(7):2087-94. doi: 10.1128/AAC.46.7.2087-2094.2002.
3
Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.
J Virol. 2001 Jun;75(11):4999-5008. doi: 10.1128/JVI.75.11.4999-5008.2001.
4
Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy.
Antimicrob Agents Chemother. 2000 Sep;44(9):2475-84. doi: 10.1128/AAC.44.9.2475-2484.2000.
5
6
A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors.
AIDS. 2003 Jan 3;17(1):F1-5. doi: 10.1097/00002030-200301030-00001.
7
Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz-based therapy in an urban observational cohort.
J Infect Dis. 2004 May 1;189(9):1688-95. doi: 10.1086/382960. Epub 2004 Apr 13.
8
Development of HIV-1 drug resistance through 144 weeks in antiretroviral-naïve subjects on emtricitabine, tenofovir disoproxil fumarate, and efavirenz compared with lamivudine/zidovudine and efavirenz in study GS-01-934.
J Acquir Immune Defic Syndr. 2009 Oct 1;52(2):209-21. doi: 10.1097/QAI.0b013e3181b05f7c.
9
Differential impact of the HIV-1 non-nucleoside reverse transcriptase inhibitor mutations K103N and M230L on viral replication and enzyme function.
J Antimicrob Chemother. 2010 Nov;65(11):2291-9. doi: 10.1093/jac/dkq338. Epub 2010 Sep 18.
10
Relative replication fitness of efavirenz-resistant mutants of HIV-1: correlation with frequency during clinical therapy and evidence of compensation for the reduced fitness of K103N + L100I by the nucleoside resistance mutation L74V.
Virology. 2006 Sep 15;353(1):184-92. doi: 10.1016/j.virol.2006.05.021. Epub 2006 Jun 21.
引用本文的文献
1
Antiretroviral Treatment of HIV-2 Infection: Available Drugs, Resistance Pathways, and Promising New Compounds.
Int J Mol Sci. 2023 Mar 21;24(6):5905. doi: 10.3390/ijms24065905.
2
Mutations in the SARS-CoV-2 RNA-dependent RNA polymerase confer resistance to remdesivir by distinct mechanisms.
Sci Transl Med. 2022 Aug 3;14(656):eabo0718. doi: 10.1126/scitranslmed.abo0718.
3
Continuation of emtricitabine/lamivudine within combination antiretroviral therapy following detection of the M184V/I HIV-1 resistance mutation.
HIV Med. 2020 May;21(5):309-321. doi: 10.1111/hiv.12829. Epub 2020 Jan 11.
4
Resistance to the Tat Inhibitor Didehydro-Cortistatin A Is Mediated by Heightened Basal HIV-1 Transcription.
mBio. 2019 Jul 2;10(4):e01750-18. doi: 10.1128/mBio.01750-18.
5
Tribute to Mark Wainberg.
Retrovirology. 2017 Jun 28;14(1):38. doi: 10.1186/s12977-017-0361-6.
6
The Geogenomic Mutational Atlas of Pathogens (GoMAP) web system.
PLoS One. 2014 Mar 27;9(3):e92877. doi: 10.1371/journal.pone.0092877. eCollection 2014.
7
The connection domain mutation N348I in HIV-1 reverse transcriptase enhances resistance to etravirine and rilpivirine but restricts the emergence of the E138K resistance mutation by diminishing viral replication capacity.
J Virol. 2014 Feb;88(3):1536-47. doi: 10.1128/JVI.02904-13. Epub 2013 Nov 13.
8
Persistence versus reversion of 3TC resistance in HIV-1 determine the rate of emergence of NVP resistance.
Viruses. 2012 Aug;4(8):1212-34. doi: 10.3390/v4081212. Epub 2012 Aug 7.
9
Subunit-selective mutational analysis and tissue culture evaluations of the interactions of the E138K and M184I mutations in HIV-1 reverse transcriptase.
J Virol. 2012 Aug;86(16):8422-31. doi: 10.1128/JVI.00271-12. Epub 2012 May 23.
10
Mutation rates and intrinsic fidelity of retroviral reverse transcriptases.
Viruses. 2009 Dec;1(3):1137-65. doi: 10.3390/v1031137. Epub 2009 Dec 4.
本文引用的文献
1
Lamivudine can exert a modest antiviral effect against human immunodeficiency virus type 1 containing the M184V mutation.
Antimicrob Agents Chemother. 2003 Feb;47(2):747-54. doi: 10.1128/AAC.47.2.747-754.2003.
2
A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors.
AIDS. 2003 Jan 3;17(1):F1-5. doi: 10.1097/00002030-200301030-00001.
3
Combination of drugs and drug-resistant reverse transcriptase results in a multiplicative increase of human immunodeficiency virus type 1 mutant frequencies.
J Virol. 2002 Sep;76(18):9253-9. doi: 10.1128/jvi.76.18.9253-9259.2002.
4
Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT.
Antimicrob Agents Chemother. 2002 Jul;46(7):2087-94. doi: 10.1128/AAC.46.7.2087-2094.2002.
5
Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection.
J Virol. 2002 Feb;76(4):1753-61. doi: 10.1128/jvi.76.4.1753-1761.2002.
6
Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy.
AIDS. 2001 Jun 15;15(9):1125-32. doi: 10.1097/00002030-200106150-00007.
7
The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis.
J Virol. 2000 Apr;74(8):3579-85. doi: 10.1128/jvi.74.8.3579-3585.2000.
8
In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA.
Antivir Ther. 1999;4(2):87-94. doi: 10.1177/135965359900400205.
9
Increased polymerase fidelity of lamivudine-resistant HIV-1 variants does not limit their evolutionary potential.
AIDS. 1999 Jul 30;13(11):1343-9. doi: 10.1097/00002030-199907300-00011.
10
Lamivudine resistance of HIV type 1 does not delay development of resistance to nonnucleoside HIV type 1-specific reverse transcriptase inhibitors as compared with wild-type HIV type 1.
AIDS Res Hum Retroviruses. 1998 Feb 10;14(3):249-53. doi: 10.1089/aid.1998.14.249.
Zotero 插件